Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
WVE | US
-0.42
-4.76%
Healthcare
Biotechnology
30/06/2024
04/10/2024
8.41
8.55
8.75
8.23
Wave Life Sciences Ltd. a clinical-stage genetic medicine company designs optimizes and produces novel stereopure oligonucleotides through PRISM a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations modulate protein activity restore the production of functional proteins or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004 a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003 a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531 an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006 the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3 a discovery stage program for the treatment of spinocerebellar ataxia 3 as well as multiple preclinical programs for CNS disorders including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc. Takeda Pharmaceutical Company Limited and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
View LessPositive Momentum
Low Debt to Asset (< 0.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
288.8%1 month
205.5%3 months
127.2%6 months
103.6%-
-
27.11
6.57
0.14
-10.12
9.96
-
-79.37M
1.24B
1.24B
-
-177.72
-
-10.90
-1.92K
6.77
5.81
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.58
Range1M
4.88
Range3M
4.88
Rel. volume
0.37
Price X volume
7.08M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 33.89 | 1.31B | 3.48% | n/a | 28.62% |
ELVN | ELVN | Biotechnology | 27.53 | 1.30B | 8.81% | n/a | 0.06% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.02 | 1.17B | -2.05% | n/a | 111.34% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 15.23 | 1.16B | 9.81% | n/a | 2662.08% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -10.12 | 0.76 | Cheaper |
Ent. to Revenue | 9.96 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 27.11 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 127.15 | 74.67 | Riskier |
Debt to Equity | 6.57 | -1.82 | Expensive |
Debt to Assets | 0.14 | 0.26 | Cheaper |
Market Cap | 1.24B | 3.73B | Emerging |